Get the Stockscreener App
37.92
0.48%
0.18
After Hours:
37.94
0.02
+0.05%
Springworks Therapeutics Inc stock is traded at $37.92, with a volume of 1.45M.
It is up +0.48% in the last 24 hours and down -23.92% over the past month.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
See More
Previous Close:
$37.74
Open:
$37.57
24h Volume:
1.45M
Relative Volume:
0.60
Market Cap:
$2.81B
Revenue:
-
Net Income/Loss:
$-275.16M
P/E Ratio:
-9.7481
EPS:
-3.89
Net Cash Flow:
$-221.15M
1W Performance:
+10.14%
1M Performance:
-23.92%
6M Performance:
+23.20%
1Y Performance:
-14.03%
1-Day Range:
$37.34
$39.03
1-Week Range:
$33.56
$39.03
52-Week Range:
$28.21
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Name
Springworks Therapeutics Inc
Sector
Industry
Phone
203-883-9490
Address
100 WASHINGTON BOULEVARD, STAMFORD, CT
Compare SWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
37.92 | 2.81B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Initiated | Evercore ISI | Outperform |
| Feb-05-24 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| Mar-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-04-19 | Initiated | H.C. Wainwright | Buy |
| Oct-08-19 | Initiated | Cowen | Outperform |
| Oct-08-19 | Initiated | Goldman | Buy |
| Oct-08-19 | Initiated | JP Morgan | Overweight |
| Oct-08-19 | Initiated | Wedbush | Outperform |
View All
Springworks Therapeutics Inc Stock (SWTX) Latest News
JPMorgan Chase & Co. Has $8.24 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
(SWTX) Investment Report - news.stocktradersdaily.com
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
SpringWorks Therapeutics Target of Unusually High Options Trading (NASDAQ:SWTX) - MarketBeat
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Russell Investments Group Ltd. Sells 27,251 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Alliancebernstein L.P. Lowers Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
BofA Adjusts Price Target on Springworks Therapeutics to $84 From $87, Keeps Buy Rating - marketscreener.com
SpringWorks Therapeutics (SWTX) Price Target Lowered by Bank of America | SWTX Stock News - GuruFocus
Fmr LLC Raises Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Norges Bank Buys New Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Down 7.1%Time to Sell? - MarketBeat
Here's Why We're Not At All Concerned With SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation - Yahoo Finance
Massachusetts Financial Services Co. MA Sells 50,547 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock Holdings Boosted by Finepoint Capital LP - MarketBeat
Vanguard Group Inc. Increases Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Schroder Investment Management Group Has $6.11 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
KLP Kapitalforvaltning AS Makes New $455,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
SpringWorks Therapeutics (NASDAQ:SWTX) Trading 5.5% HigherHere's Why - MarketBeat
NEOS Investment Management LLC Increases Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Pictet Asset Management Holding SA Has $86.40 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Stock Surge: An Investor’s Dilemma - timothysykes.com
SpringWorks Therapeutics Enters Oversold Territory (SWTX) - Nasdaq
BIT Capital GmbH Increases Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Segall Bryant & Hamill LLC Has $6.99 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Cibc World Markets Corp Acquires New Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Swiss National Bank Has $4.22 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Down 2.5%Time to Sell? - MarketBeat
SpringWorks Therapeutics Target of Unusually Large Options Trading (NASDAQ:SWTX) - MarketBeat
Neurofibromatosis Type 2 Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Recursion Pharma, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics - Barchart
Neurofibromatosis Type 2 Pipeline 2025: Key Companies, MOA, - openPR
Raymond James Financial Inc. Invests $10.53 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
46,895 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Purchased by Platinum Investment Management Ltd. - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 4.8%Should You Sell? - MarketBeat
Springworks Therapeutics Inc Stock (SWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):